Deutsche Bank AG Invests $33.56 Million in Smith & Nephew SNATS, Inc. $SNN

Deutsche Bank AG purchased a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the second quarter, HoldingsChannel reports. The institutional investor purchased 535,130 shares of the medical equipment provider’s stock, valued at approximately $33,563,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Clearstead Trust LLC bought a new position in Smith & Nephew SNATS in the 2nd quarter valued at approximately $25,000. Garner Asset Management Corp bought a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth $27,000. Arax Advisory Partners increased its holdings in shares of Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 569 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Smith & Nephew SNATS during the fourth quarter worth $36,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Smith & Nephew SNATS in the 3rd quarter valued at $41,000. 25.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SNN has been the topic of a number of research reports. Barclays lowered Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. Zacks Research downgraded Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Smith & Nephew SNATS in a report on Wednesday, August 5th. Finally, Wall Street Zen downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Sunday, August 16th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Smith & Nephew SNATS currently has a consensus rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Price Performance

Shares of SNN opened at $29.29 on Friday. Smith & Nephew SNATS, Inc. has a 52-week low of $28.56 and a 52-week high of $38.79. The business’s 50 day moving average price is $30.32 and its two-hundred day moving average price is $31.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11.

Smith & Nephew SNATS Dividend Announcement

The business also recently declared a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be issued a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.